



# Bristol-Myers Squibb Company

Worldwide Medicines Group

P.O. Box 4000 Princeton, NJ 08543-4000 Tel: 609 252-5914; Fax: 609 252-4526

Date October 30, 2003

## FACSIMILE TRANSMITTAL SHEET

TO: Examiner Vickey Kim

FACSIMILE NO: 703-746-3165

TELEPHONE NO: 703-305-1675

FROM: Jing Belfield

TELEPHONE NO: 609-252-3791

COMPANY: Bristol-Myers Squibb Company

FACSIMILE NO: 609-252-4526

TOTAL NUMBER OF PAGES INCLUDING THIS COVER PAGE: 13

If you do not receive a complete fax please contact Hilda Franco at 609-252-5914

Re: **Docket No. PH7038; USSN 09/519,188; Filed: March 6, 2000; Wong, et al.**

As discussed enclosed is the Amendment and Request for Reconsideration dated  
July 29, 2003.

**OFFICIAL**  
**RECEIVED**  
**CENTRAL FAX CENTER**  
OCT 31 2003

Docket No.: PH-7038  
USSN: 09/519,188

Docket Number	PH-7038
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV323500379US Express Mail Label Number	July 29, 2003 Date of Deposit

RECEIVED  
CENTRAL FAX CENTER  
OCT 31 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appln. of: Wong	)	U.S. Serial No.: 09/519,188
	)	
Filed: 03/06/2000	)	Examiner: Kim, V.
	)	Art Unit: 1614
For: Treatment of Thrombosis by	)	
Combined Use of a Factor Xa	)	
Inhibitor and Aspirin, Tissue	)	
Plasminogen Activator (TPA)	)	
a GPIIb/IIIa Antagonist, Low	)	
Molecular Weight Heparin or	)	
Heparin	)	

Hon. Assistant Commissioner for Patents  
Washington, D.C. 20231

Date: July 29, 2003

Dear Sir:

**AMENDMENT AND REQUEST FOR RECONSIDERATION**

Responsive to the Office Action dated April 3, 2003, Applicant respectfully requests reconsideration in view of the following amendment and remarks.